You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES

HIGHLIGHTS

EVENTS

Kedrion Biopharma supports the 2020 Primary Immunodeficiency Week

The company stands alongside the global PI community

read more 

CORPORATE

Kedrion and Kamada announce collaboration for Anti Covid-19 IgG

read more 

EVENTS

World Hemophilia Day: socially distant but still united with patients

Now more than ever, Kedrion is renewing its commitment to those who live with this rare disorder

read more 

  1. CORPORATE - 17-04-2014

    5-year unrated EUR 300 million bond successfully launched

    The bonds have been placed with leading international institutional investors and will be listed on the Irish Stock Exchange

    read more 

  2. CORPORATE - 16-04-2014

    Kedrion Group approves 2013 financial statements

    Achieved results of 425 million euros turnover and a 25% profitability

    read more 

  3. PLASMA & BIOTHERAPIES - 14-04-2014

    Kedrion collection centers first to be certified in Hungary

    Plazmaferezis Állomás Kft achieves international PPTA certification

    read more 

  4. EVENTS - 01-04-2014

    Kedrion supports World Hemophilia Day

    The goal is to improve access to treatments for people suffering from hemophilia and other hemorrhagic conditions

    read more 

Pages

For more information please contact: pressoffice@kedrion.com